[{"id":"354295c1-22c1-46a8-9795-aed719694630","acronym":"","url":"https://clinicaltrials.gov/study/NCT05942300","created_at":"2023-07-12T15:08:55.008Z","updated_at":"2025-02-25T15:28:10.507Z","phase":"Phase 1","brief_title":"CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer","source_id_and_acronym":"NCT05942300","lead_sponsor":"Lan Coffman","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • tulmimetostat (DZR123)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/10/2024","start_date":" 01/10/2024","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-02-11"},{"id":"64837254-ecf8-44d3-8267-0595bd882719","acronym":"","url":"https://clinicaltrials.gov/study/NCT05633979","created_at":"2022-12-01T15:57:19.166Z","updated_at":"2025-02-25T15:27:45.382Z","phase":"Phase 1","brief_title":"Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer","source_id_and_acronym":"NCT05633979","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • UGT1A1","pipe":"","alterations":" ","tags":["HER-2 • UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • Ezharmia (valemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 02/09/2023","start_date":" 02/09/2023","primary_txt":" Primary completion: 12/31/2030","primary_completion_date":" 12/31/2030","study_txt":" Completion: 12/31/2032","study_completion_date":" 12/31/2032","last_update_posted":"2025-02-10"},{"id":"15a57807-96a4-44c8-8faf-02682afe4492","acronym":"VALYM","url":"https://clinicaltrials.gov/study/NCT04842877","created_at":"2021-04-13T13:30:33.989Z","updated_at":"2025-02-25T16:26:30.882Z","phase":"Phase 2","brief_title":"Study of Valemetostat Tosylate as a Single Agent in Patients With Relapse/Refractory B-cell Lymphoma","source_id_and_acronym":"NCT04842877 - VALYM","lead_sponsor":"The Lymphoma Academic Research Organisation","biomarkers":" SLC1A5","pipe":" | ","alterations":" EZH2 mutation","tags":["SLC1A5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EZH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ezharmia (valemetostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 141","initiation":"Initiation: 06/11/2021","start_date":" 06/11/2021","primary_txt":" Primary completion: 12/03/2024","primary_completion_date":" 12/03/2024","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-01-24"},{"id":"46a1e98d-dee3-4d71-a1e5-aefae695a396","acronym":"KEYNOTE-F85","url":"https://clinicaltrials.gov/study/NCT06644768","created_at":"2025-02-25T16:02:58.459Z","updated_at":"2025-02-25T16:02:58.459Z","phase":"Phase 1/2","brief_title":"A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations","source_id_and_acronym":"NCT06644768 - KEYNOTE-F85","lead_sponsor":"Daiichi Sankyo","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Ezharmia (valemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 10/30/2024","start_date":" 10/30/2024","primary_txt":" Primary completion: 03/30/2028","primary_completion_date":" 03/30/2028","study_txt":" Completion: 04/30/2030","study_completion_date":" 04/30/2030","last_update_posted":"2024-11-14"},{"id":"7d21338e-ff73-41cf-853f-9516a337a92e","acronym":"FIH","url":"https://clinicaltrials.gov/study/NCT04104776","created_at":"2021-08-13T14:52:51.135Z","updated_at":"2025-02-25T15:43:41.485Z","phase":"Phase 1/2","brief_title":"A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas","source_id_and_acronym":"NCT04104776 - FIH","lead_sponsor":"Constellation Pharmaceuticals","biomarkers":" MSI • ARID1A • BAP1","pipe":" | ","alterations":" MSI-H/dMMR • ARID1A mutation","tags":["MSI • ARID1A • BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • tulmimetostat (DZR123)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 09/18/2019","start_date":" 09/18/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-08-02"},{"id":"f7eb27f3-8b9e-4d94-9852-c62cefd66a29","acronym":"","url":"https://clinicaltrials.gov/study/NCT04388852","created_at":"2021-01-18T21:11:08.040Z","updated_at":"2024-07-02T16:35:03.232Z","phase":"Phase 1","brief_title":"DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers","source_id_and_acronym":"NCT04388852","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • TP53 • PTEN • RB1","pipe":"","alterations":" ","tags":["PD-L1 • TP53 • PTEN • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • Ezharmia (valemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/20/2020","start_date":" 08/20/2020","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-16"},{"id":"64c0eae1-673c-4049-a5b1-8479f1fe1ac9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05683171","created_at":"2023-01-13T15:59:24.110Z","updated_at":"2024-07-02T16:35:04.648Z","phase":"Phase 1/2","brief_title":"A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma","source_id_and_acronym":"NCT05683171","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1 • UGT1A1 mutation","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1 • UGT1A1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • lenalidomide • Ezharmia (valemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/19/2023","start_date":" 05/19/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-09"},{"id":"a42b730f-7cb0-4a7e-b9c9-5253a2b3eeb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04390737","created_at":"2022-05-12T19:53:40.351Z","updated_at":"2024-07-02T16:35:04.605Z","phase":"Phase 1/2","brief_title":"Evaluate the Safety and Clinical Activity of HH2853","source_id_and_acronym":"NCT04390737","lead_sponsor":"Haihe Biopharma Co., Ltd.","biomarkers":" ARID1A • BAP1","pipe":" | ","alterations":" ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation","tags":["ARID1A • BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ARID1A mutation • BAP1 mutation • EZH2 mutation • SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HH2853"],"overall_status":"Recruiting","enrollment":" Enrollment 254","initiation":"Initiation: 09/08/2020","start_date":" 09/08/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-09"},{"id":"4b00b49c-05e6-4442-a15d-1f3b8ac293cc","acronym":"VALENTINE-PTCL01","url":"https://clinicaltrials.gov/study/NCT04703192","created_at":"2021-01-19T20:51:00.905Z","updated_at":"2024-07-02T16:35:09.833Z","phase":"Phase 2","brief_title":"Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)","source_id_and_acronym":"NCT04703192 - VALENTINE-PTCL01","lead_sponsor":"Daiichi Sankyo","biomarkers":" ALK • CD8","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ezharmia (valemetostat)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 148","initiation":"Initiation: 06/03/2021","start_date":" 06/03/2021","primary_txt":" Primary completion: 05/10/2023","primary_completion_date":" 05/10/2023","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-04-12"}]